Leucocytopenia after rifampicin and ofloxacin therapy in leprosy

Leprosy Review

Volumn 68, Issue 1, 1997, Pages 10-15

  Vijayakumaran, P ^a   Manimozhi, N ^a   Jesudasan, K ^a   Arunthathi, S ^a   Jacob, Mary ^a   Samuel, P ^a  

^a Schieffelin Leprosy Res Train Ctr   (India)

Author keywords

[No Author keywords available]

Indexed keywords

LEPROSTATIC AGENT; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN;

ADULT; ANOREXIA; ARTICLE; FEMALE; FEVER; HUMAN; LEPROSY; LEUKOPENIA; MAJOR CLINICAL STUDY; MALAISE; NAUSEA;

EID: 0030993587     PISSN: 03057518     EISSN: None     Source Type: Journal    
DOI: 10.5935/0305-7518.19970003     Document Type: Article

References (17)

1. WHO Expert Committee on Leprosy: Sixth report. Technical Report Series 1988 (No. 768): 51 pp.
2. Girdhar BK. Multidrug therapy in leprosy and its future components. Ind J Lepr, 1994; 66(2): 179-208.
3. Franzblau SG, White KE. Comparative in vitro activities of 20 fluoroquinolones against Mycobacterium leprae. Antimicrob Agents Chemother, 1990 Feb; 34(2): 229-31.
4. Saito H, Tomioka H, Nagashima K. In vivo and in vivo activities of ofloxacin against Mycobacterium leprae infection induced in mice. Int J Lepr, 1986; 54(4): 560-2.
5. Grosset JH, Guelpa-Lauras CC, Perani EG, Beoletto C. Activity of ofloxacin against Mycobacterium leprae in the mouse. Int J Lepr, 1988; 56(2): 259-264.
6. Grosset JH, Ji BH, Guelpa-Lauras CC, Perani EG, N'Deli LN. Clinical trial of pefloxacin and ofloxacin in the treatment of lepromatous leprosy. Int J Lepr, 1990; 58(2): 281-95.
7. 2-Fe - mediated halogenation system supplemented with antimicrobial agents. Int J Lepr, 1989; 57(3): 628-32.
8. Chandorkar AG, Burte NP, Gade RK, Bulakh PM. Once monthly rifampicin (1200 mg) plus daily dapsone (100 mg) and clofazimine (100 mg) in the initial treatmnt of lepromatous leprosy. Ind J Lepr, 1984; 56(1): 63-70.
9. Jopling WH. Editorial on Side-effects of antileprosy drugs in common use. Lepr Rev, 1983; 54: 261-270.
10. Parking AA, Shah BH. Flu like syndrome with rifampicin pulse therapy. Ind J Lepr, 1989 Apr; 61(2): 209-10.
11. Cartel JL, Millan J, Guelpa-Lauras CC, Grosset JH. Hepatitis in leprosy patients treated by a daily combination of dapsone, rifampicin and a thiomide. Int J Lepr, 1984; 51(4): 461-465.
12. Pattyn SR et al. Hepatotoxicity of the combination of rifampicin-ethionamide in the treatment of leprosy. Int J Lepro, 1984; 52(1): 1-6.
13. Gluckman E, Roudet C, Hirsch I, Devergie A, Bourdeau H, Arlet C, Perol Y. Prophylaxis of bacterial infections after bone marrow transplantation. A randomized prospective study comparing oral broad-spectrum nonabsorbable antibiotics (vancomycin-tobramycin-colistin) to absorbable antibiotics (ofloxacin-amoxicillin). Chemotherapy, 1991; 37 Suppl 1: 33-8.
14. Mary HH, Chandler et al. Multiple dose pharmacokinetics of concurrent oral ciprofloxacin and rifampicin therapy in elderly patients. Antimicrobial Agents Chemotherapy, 1990, pp. 442-47.
15. Michel Drancourt et al. Oral rifampicin plus ofloxacin for treatment of staphylococcus infected orthopedic implants. Antimicrobial Agents Chemotherapy, 1993, 37(6) pp. 1214-218.
16. Murat Akova et al. Quinolones in treatment of human Burcellosis. Comparative trial ofloxacin-rifampin versus doxycycline-rifampin. Antimicrobial Agents Chemotherapy. Sep 1993, 37(9) pp 1831-834.
17. Wolfson JS. Quinolone antimicrobial agents: adverse effects and bacterial resistance. Eur J Clin Microbiol Infect Dis, 1989; 1081-1091.